Perrigo Company plc Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- Perrigo Company plc payments for repurchase of common stock for the quarter ending 2019-03-30 was $0.00, a 100.00% decline year-over-year.
- Perrigo Company plc payments for repurchase of common stock for the quarter ending 2018-12-31 was $0.00.
- Perrigo Company plc payments for repurchase of common stock for the quarter ending 2018-09-29 was $135.00M, a 1.28% increase year-over-year.
- Perrigo Company plc payments for repurchase of common stock for the quarter ending 2018-06-30 was $156.90M, a 169.59% increase year-over-year.
- Perrigo Company plc payments for repurchase of common stock for fiscal 2022 was $0.00.
- Perrigo Company plc payments for repurchase of common stock for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- Perrigo Company plc payments for repurchase of common stock for fiscal 2020 was $164.20M.
- Perrigo Company plc payments for repurchase of common stock for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 | |
| 2021-12-31 | $0.00 10-K · filed 2023-02-28 | |
| 2020-12-31 | $164.20M 10-K · filed 2023-02-28 | |
| 2019-12-31 | $0.00 10-K · filed 2022-03-01 | |
| 2019-03-30 | $0.00 10-Q · filed 2019-05-09 | $291.90M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $400.00M 10-K · filed 2021-03-01 |
| 2018-09-29 | $135.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $400.00M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $156.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $398.30M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $108.10M 10-Q · filed 2019-05-09 | $299.60M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $191.50M 10-K · filed 2020-02-27 |
| 2017-09-30 | $133.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $191.50M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-07-01 | $58.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $58.20M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-04-01 | $0.00 10-Q · filed 2018-05-08 | $0.00 derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $0.00 10-K · filed 2019-02-27 |
| 2016-10-01 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $491.00M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-07-02 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2017-08-10 | $500.00M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-04-02 | $0.00 10-Q/A · filed 2017-05-22 | $492.30M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-12-31 | $491.00M derived: 10-K 6 month − 10-Q 3 month · filed 2018-03-01 | $492.40M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-09-26 | $9.00M 10-Q · filed 2015-11-02 | $1.60M derived: sum of 4 quarters · filed 2018-03-01 |
| 2015-06-27 | -$7.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $0.00 10-K · filed 2018-03-01 |
| 2015-03-28 | $100.00K 10-Q/A · filed 2017-05-22 | $300.00K derived: sum of 4 quarters · filed 2017-05-22 |
| 2014-12-27 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-02-05 | $400.00K derived: sum of 4 quarters · filed 2017-05-22 |
| 2014-09-27 | $7.50M 10-Q · filed 2015-11-02 | $200.00K derived: sum of 4 quarters · filed 2017-05-22 |
| 2014-06-28 | -$7.50M derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | $0.00 10-K · filed 2017-05-22 |
| 2014-03-29 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-04-29 | -$4.80M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-28 | $0.00 derived: 10-Q 6 month − 8-K 3 month · filed 2015-02-05 | -$4.90M derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-09-28 | $7.30M 8-K · filed 2014-11-20 | |
| 2013-06-29 | -$12.30M derived: 10-KT 12 month − 10-Q 9 month · filed 2016-02-25 | $0.00 10-KT · filed 2016-02-25 |
| 2013-03-30 | $100.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-07 | |
| 2012-06-30 | $8.20M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |